Xenazine Related Published Studies
Well-designed clinical trials related to Xenazine (Tetrabenazine)
Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week,
double-blind, placebo-controlled trial. [2012]
Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. [2009.12.18]
A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. [2008.05]
Well-designed clinical trials possibly related to Xenazine (Tetrabenazine)
Oral pharmacological treatment of X-linked dystonia parkinsonism: successes and failures. [2011]
Other research related to Xenazine (Tetrabenazine)
Tetrabenazine for the treatment of tardive dyskinesia. [2011.04]
Management of Huntington's disease: role of tetrabenazine. [2011]
Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. [2010.08]
Role of tetrabenazine for Huntington's disease-associated chorea. [2010.06]
A case of PANDAS treated with tetrabenazine and tonsillectomy. [2010.05]
Tetrabenazine. [2009.12]
Pelvic dyskinesia with an outstanding response to tetrabenazine. [2009.08.01]
Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. [2009.07]
[Therapeutic use of tetrabenazine] [2009.05.16]
Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. [2009.01.15]
The long-term effect of tetrabenazine in the management of Huntington disease. [2008.11]
Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs. [2008.04]
Tourette's syndrome and role of tetrabenazine: review and personal experience. [2008]
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. [2007.01.15]
Short-term effects of tetrabenazine on chorea associated with Huntington's disease. [2007.01]
Other possibly related research studies
Therapeutic interventions for disease progression in Huntington's disease. [2009.07.08]
Signal separation and parameter estimation in noninvasive dual-tracer PET scans using reference-region approaches. [2009.07]
Visualizing vesicular dopamine dynamics in Parkinson's disease. [2009.08]
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? [2008.09.24]
Anterocollis: clinical features and treatment options. [2008.09]
[Severe generalized dystonia due to postradiotherapy cerebral calcifications] [2008.05]
Treatment of tardive dyskinesia with levetiracetam in a transplant patient. [2008.05]
A systematic review of the treatment studies in Huntington's disease since 1990. [2007.02]
Vesicular monoamine transporter 1 mediates dopamine secretion in rat proximal tubular cells. [2007.05]
Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. [2010.09]
In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease. [2010.05]
Advances in the pharmacological management of Huntington's disease. [2010.03.26]
Wilson's disease--a rare psychiatric presentation. [2009.07]
A case of secondary dystonia responding to levodopa. [2010.06]
Treatment of hyperkinetic movement disorders. [2009.09]
Increased beta activity in dystonia patients after drug-induced dopamine deficiency. [2008.11]
An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease. [2011.08.30]
Post pump chorea in a 77-year-old male. [2011.08]
Huntington's disease: From molecular basis to therapeutic advances. [2011.01]
Tardive dyskinesia and other movement disorders secondary to aripiprazole. [2011.01]
The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. [2010.12]
Reserpine causes biphasic nociceptive sensitivity alteration in conjunction with brain biogenic amine tones in rats. [2010.09.15]
The effect of chronic methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD. [2010.10]
An evidence-based approach in the treatment of Huntington's disease. [2012]
|
